@article{ref1,
title="The prevalence and clinical features of amphetamine-induced obsessive compulsive disorder",
journal="Drug and alcohol dependence",
year="2016",
author="Shakeri, Jalal and Farnia, Vahid and Karimi, Ali Reza and Tatari, Faeze and Juibari, Touraj Ahmadi and Alikhani, Mostafa and Bajoghli, Hafez and Holsboer-Trachsler, Edith and Brand, Serge",
volume="160",
number="",
pages="157-162",
abstract="BACKGROUND: Amphetamine abuse is increasing worldwide, and the occurrence of amphetamine-induced (AI) psychiatric issues further complicates treatment. In response, the DSM 5 has introduced the classification of amphetamine-induced obsessive-compulsive disorders (AI-OCD), though little has been published on either its prevalence rates or its clinical features. The aim of the present study was therefore to investigate the prevalence of AI-OCD, to describe patients' clinical features, and to compare the prevalence rate among such patients with those for OCD in the general population in Western countries and Iran. <br><br>METHODS: A total of 547 patients with amphetamine abuse or dependency and with a positive urine test (mean age: 31.64 years; 75.5% males) took part in the study. A psychiatric interview was carried out, covering both socio-demographic and illness-related information. <br><br>RESULTS: 18 (3.3%) patients suffered from OCD prior to amphetamine abuse, 491 (89.8%) had no OCD, and 38 (6.9%) suffered from AI-OCD. Neither socio-demographic nor illness-related dimensions predicted patients with diagnosed AI-OCD. The prevalence of AI-OCD was significantly higher than that for OCD in the general population (2.3% in Western countries, 1.8% in Iran). <br><br>CONCLUSIONS: Data suggest that prevalence rate of AI-OCD is about 7%. Neither socio-demographic nor illness-related dimensions predicted the occurrence of AI-OCD. Thus, it remains unclear why some amphetamine abusers develop AI-OCD while others do not.<p /> <p>Language: en</p>",
language="en",
issn="0376-8716",
doi="10.1016/j.drugalcdep.2015.12.034",
url="http://dx.doi.org/10.1016/j.drugalcdep.2015.12.034"
}